Amarin Corporation (AMRN) Get's A Wider Label 2 Weeks Before PDUFA - Roth Capital
Tweet Send to a Friend
Roth Capital analyst Yasmeen Rahimi reiterated a Buy rating and $31.00 price target on Amarin Corporation (NASDAQ: AMRN) after Vascepa ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
